At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ITP IT Tech Packaging Inc
Post-Mkt 08-03 18:16:04 EDT
0.1790
+0.0040
+2.29%
盘后0.1790
+0.00000.00%
16:10 EDT
High0.1835Low0.1750Vol406.15K
Open0.1800D1 Closing0.1750Amplitude4.86%
Mkt Cap3.04MTradable Cap2.94MTotal Shares16.97M
T/O72.83KT/O Rate2.47%Tradable Shares16.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire  ·  07-30
Agios Reports Second Quarter 2026 Financial Results and Provides Business Update
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
GlobeNewswire  ·  07-16
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Press Release: Bionano Announces Hiring of Chief Scientific Officer
Dow Jones  ·  06-24
Press Release: Bionano Announces Hiring of Chief Scientific Officer
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
GlobeNewswire  ·  06-11
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
Climb Bio Reports Encouraging Early Budoprutug ITP Data
TIPRANKS  ·  06-11
Climb Bio Reports Encouraging Early Budoprutug ITP Data
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
GlobeNewswire  ·  06-11
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
GlobeNewswire  ·  06-10
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
GlobeNewswire  ·  06-03
argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
GlobeNewswire  ·  06-01
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
InnoCare Pharma Gets Acceptance for ITP New Drug Application; Shares Up 3%
MT Newswires Live  ·  05-29
InnoCare Pharma Gets Acceptance for ITP New Drug Application; Shares Up 3%
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
GlobeNewswire  ·  05-28
Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures
InnoCare’s ITP Drug Filing for Orelabrutinib Accepted by China Regulator
TIPRANKS  ·  05-28
InnoCare’s ITP Drug Filing for Orelabrutinib Accepted by China Regulator
Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
GlobeNewswire  ·  05-26
Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
GlobeNewswire  ·  05-26
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
US$800 million commitment achieved by FAST-P initiative Green Investments Partnership
Lin Daoyi  ·  05-20
US$800 million commitment achieved by FAST-P initiative Green Investments Partnership
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
GlobeNewswire  ·  05-14
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
IT Tech Packaging delays Q1 Form 10-Q filing, seeks 5-day extension
Reuters  ·  05-14
IT Tech Packaging delays Q1 Form 10-Q filing, seeks 5-day extension
Press Release: Bionano Reports First Quarter 2026 Results and Provides a Business Update
Dow Jones  ·  05-14
Press Release: Bionano Reports First Quarter 2026 Results and Provides a Business Update
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire  ·  05-07
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire  ·  05-07
argenx Reports First Quarter 2026 Financial Results and Provides Business Update

Introduction

Company Name.
IT Tech Packaging Inc
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
IT Tech Packaging, Inc., together with its subsidiaries, engages in the production and distribution of paper products in the People's Republic of China. The company operates through three segments: Dongfang Paper, Tengsheng Paper, and Baoding Shengde. It offers corrugating medium papers to companies making corrugating cardboards; and offset printing papers to printing companies. The company also provides tissue paper products, including toilet papers, boxed and soft-packed tissues, handkerchief tissues, and paper napkins, as well as bathroom and kitchen paper towels under the Dongfang Paper brand. In addition, it produces and sells non-medical single-use face masks, and medical face masks. The company was formerly known as Orient Paper, Inc. and changed its name to IT Tech Packaging, Inc. in August 2018. The company is headquartered in Baoding, the People's' Republic of China.
Issue price:
--